Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 487 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 487 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $22.00, for a total transaction of $10,714.00. Following the transaction, the insider owned 406,288 shares in the company, valued at approximately $8,938,336. The trade was a 0.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $19.00, for a total transaction of $95,000.00.
• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total value of $198,000.00.

Adaptive Biotechnologies Stock Performance

NASDAQ ADPT opened at $21.50 on Tuesday. Adaptive Biotechnologies Corporation has a fifty-two week low of $9.96 and a fifty-two week high of $22.80. The firm’s fifty day moving average price is $16.24 and its two-hundred day moving average price is $15.90. The stock has a market cap of $3.44 billion, a PE ratio of -65.15 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company’s revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.20) EPS. As a group, sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC boosted its stake in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares in the last quarter. KBC Group NV bought a new position in Adaptive Biotechnologies during the first quarter worth $45,000. Assetmark Inc. grew its holdings in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in Adaptive Biotechnologies in the fourth quarter worth $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ADPT. BTIG Research reissued a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Guggenheim lifted their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Morgan Stanley reduced their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.